tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Abeona Therapeutics’ Earnings Call Highlights ZEVASKYN Success
PremiumCompany AnnouncementsAbeona Therapeutics’ Earnings Call Highlights ZEVASKYN Success
2M ago
Abeona Therapeutics price target raised to $20 from $19 at Oppenheimer
Premium
The Fly
Abeona Therapeutics price target raised to $20 from $19 at Oppenheimer
2M ago
Abeona Therapeutics Reports Strong Financial Turnaround
Premium
Company Announcements
Abeona Therapeutics Reports Strong Financial Turnaround
2M ago
Abeona Therapeutics Amends Loan Agreement with Avenue
PremiumCompany AnnouncementsAbeona Therapeutics Amends Loan Agreement with Avenue
3M ago
Abeona announces ZEVASKYN available at new Qualified Treatment Center
Premium
The Fly
Abeona announces ZEVASKYN available at new Qualified Treatment Center
3M ago
Positive Outlook for Abeona Therapeutics Amid FDA Challenges and Promising ZEVASKYN Launch
Premium
Ratings
Positive Outlook for Abeona Therapeutics Amid FDA Challenges and Promising ZEVASKYN Launch
3M ago
Abeona Therapeutics added to membership of Russell 2000, Russell 3000
PremiumThe FlyAbeona Therapeutics added to membership of Russell 2000, Russell 3000
4M ago
Abeona Therapeutics announces publication in The Lancet of Phase 3 VITAL study
Premium
The Fly
Abeona Therapeutics announces publication in The Lancet of Phase 3 VITAL study
4M ago
Abeona Therapeutics assumed with an Outperform at Oppenheimer
Premium
The Fly
Abeona Therapeutics assumed with an Outperform at Oppenheimer
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100